Straumann Holding AG · SIX:STMN
Straumann — Goldman Sachs European Medtech Conference 2008
17 slides from Straumann's conference presentation, Sep 3, 2008
Slide 1: To be a true solution provider
To be a true solution provider Gilbert Achermann, President & CEO Goldman Sachs European Medtech Conference 2008 Wednesday, 3 September 2008
Slide 2: Our substitution technologies
Our substitution technologies Treatment Manufacturing Materials Crowns and bridges Traditional manufacturing Metals Collagen membranes 2009 Dental implants CAD/CAM prosthetics Ceramics Hydrogel membranes STRAUMANN 2 7 August 2008
Slide 3: Markets characterized by low treatment rates…
Markets characterized by low treatment rates… Annual implant treatment rates Growth forecast for the dental in developed countries implant market STRAUMANN Source: MRG and Straumann estimates. 3 7 August 2008
Slide 4: We have considerably expanded our portfolio
We have considerably expanded our portfolio STRAUMANN 4 7 August 2008
Slide 5: Market sector size
Straumann's business scope is focused on the fastest growing sectors in dentistry 10 Market sector size* Prosthetics 8 in CHF bn 6 Dental equipment 4 Implant dentistry (incl. implants & abutments) Endodontic 2 Infection CAD/CAM dentistry control Orthodontic Regenerative dentistry Preventive Restorat
Slide 6: Straumann is active in three highly attractive dental areas worth together CHF 5bn
Straumann is active in three highly attractive dental areas worth together CHF 5bn Implant dentistry CAD/CAM dentistry Regenerative dentistry market* 2007 market* 2007 market* 2007 100% = CHF 3.3bn 100% = CHF 1.1bn 100% = CHF 0.3bn Straumann Straumann Straumann 17% <5% <10% Others 30% Nobel Biocare
Slide 7: Straumann leads the Tissue Level segment… …and entered the Bone Level arena end of 2007
Implants Straumann leads the Tissue Level segment… …and entered the Bone Level arena end of 2007 Implant dentistry* 2007 100% = CHF 3.3 bn New 17% Bone Level Soft Tissue Level 60-70% 30-40% = Straumann market share * Source: MRG; iDATA, Straumann Schätzungen 7 STRAUMANN 7 August 2008
Slide 8: SLActive in a class of its own with more potential
Implants SLActive in a class of its own with more potential Removal torque Ncm/mm2 1.2 Multicenter study 1-year results1 show 1 exceptional survival rates, despite >40% 0.8 SLActive of implants being placed in poor quality 0.6 bone Î immediate loading = 98% survival 0.4 Main competitor Î early loadi
Slide 9: Straumann serves ALL customer segments
Straumann serves ALL customer segments Surgical Regeneratives Prosthetics etkon Dental General dentists Dental specialists* (DMD/DDS)** technician ● Increases access to segments Network ● Increases share of wallet ● Protects franchise * Surgically active dental professionals irrespective of specialt
Slide 10: Business performance
Z straumann Business performance COMMITTED TO SIMPLY DOING MORE FOR DENTAL PROFESSIONALS
Slide 11: Accelerated organic growth lifts revenue 22% (l.c.)
Accelerated organic growth lifts revenue 22% (l.c.) H1 2008 net revenue growth in % Organic growth2 by quarter in % (l.c.) Total Group: CHF 413 million + 4.5% - 5.3% 20% 20% 18% + 0.4% 16% 14% 13% 13% 13% 12% 12% 12% 11% 10% 10% 21.9% 17.4% 16.6% 17.0% Growth Currency Growth l.c. Acquisition Growth
Slide 12: Solid market position underpinned
Solid market position underpinned #2 # #1 1 market#share 2 Ü market share Ö market share Ö market share Ü #3 market share Þ * Bubble size indicates regional implant market size in 2007. STRAUMANN 12 7 August 2008
Slide 13: Gross profit margin of underlying business expanded by 100 basis points
Gross profit margin of underlying business expanded by 100 basis points In % of net revenue + 1.0% - 0.6% - 0.3% COGS: COGS: CHF 62.9m CHF 73.6m 82.8% 82.1% 81.8% 82.2% Gross Profit FX effect Gross Profit Productivity Underlying Acquired Gross Profit H12007 (%) H12007 (%) at improvement Gross Profit
Slide 14: 2008 guidance confirmed
2008 guidance confirmed (barring unforeseen circumstances) On the basis of the underlying performance in the first half and the expected contributions from new products, technologies and subsidiaries, Straumann expects 2008 full-year revenue growth to be in the low to mid twenties range in local cur
Slide 15: Questions & answers
straumann ANN Questions & answers COMMITTED TO SIMPLY DOING MORE FOR DENTAL PROFESSIONALS
Slide 16: Your Investor contacts
Your Investor contacts Head of Investor Relations Fabian Hildbrand Phone +41 (0)61 965 13 27 Mobile +41 (0)79 392 80 32 Email [email protected] Investor Relations Coordination Bettina Schiendorfer Phone +41 (0)61 965 16 35 Email [email protected] STRAUMANN 16 7 August 2
Slide 17: Disclaimer
Disclaimer This presentation contains certain “forward-looking statements”, which can be identified by use of terminology such as “expect”, “expectation”, “intend”, “continue”, “achieve”, “maintain”, “improve”, “foresee”, “anticipate”, “product introductions”, “outlook”, “forecast”, or similar wordi
Straumann Holding — Goldman Sachs European Medtech Conference 2008 on 6ix